Hopkins K, Kemshead J T
Imperial Cancer Research Fund, Frenchay Hospital, Bristol, UK.
J Drug Target. 1993;1(3):175-83. doi: 10.3109/10611869308996074.
The systemic administration of monoclonal antibodies (MoAbs) as delivery vehicles for targeted radiation therapy is associated with many problems. Most studies show that insufficient isotope is taken up into the tumour to elicit a tumoricidal effect. This has led several groups to explore the administration of radiolabelled MoAbs into body compartments, specifically for the treatment of minimal tumour deposits that present either as malignant ascites or small nodules on the lining of body cavities. The use of 131Iodine (131I) labelled MoAbs in the treatment of disseminated disease in the central nervous system (CNS) is described and the possibility of administering radiolabelled MoAbs to a cavity generated after debulking surgery for malignant glioma in order to overcome the problem of poor MoAb uptake into solid tumour deposits is discussed together with the rationale for substituting 90Yttrium (90Y) for 131I.
将单克隆抗体（MoAbs）作为靶向放射治疗的递送载体进行全身给药存在许多问题。大多数研究表明，肿瘤摄取的同位素不足，无法产生杀肿瘤效应。这使得多个研究小组探索将放射性标记的单克隆抗体注入体腔，专门用于治疗以恶性腹水或体腔壁上小结节形式存在的微小肿瘤沉积物。本文描述了使用131碘（131I）标记的单克隆抗体治疗中枢神经系统（CNS）播散性疾病的情况，并讨论了在恶性胶质瘤减瘤手术后向所形成的腔隙中注入放射性标记单克隆抗体以克服单克隆抗体在实体肿瘤沉积物中摄取不佳问题的可能性，以及用90钇（90Y）替代131I的原理。
